Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 1,573 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Biological Control Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine

NCT04009824
View directory record Official record
Conditions
Mosquito-Borne Infectious Diseases
Interventions
AGS-v PLUS Vaccine, Montanide ISA-51 Adjuvant, Alhydrogel® Adjuvant, Saline Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 25, 2026, 2:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Trial of Gabapentin in Vulvodynia: Biological Correlates of Response

NCT01301001
View directory record Official record
Conditions
Vulvodynia
Interventions
Placebo oral capsule, Gabapentin
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older · Female only
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
3
States / cities
New Brunswick, New Jersey • Rochester, New York • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 25, 2026, 2:05 PM EDT
Completed Not applicable Interventional

The CORRONA Treat to Target Trial: Outcomes and Feasibility in a US Population

NCT01407419
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Treatment Acceleration, Monthly Assessment
Other
Lead sponsor
CorEvitas
Network
Eligibility
18 Years and older
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 25, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device

NCT02146781
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
CryJ2-DNA-LAMP plasmid vaccine by intradermal injection, Saline Control
Biological · Other
Lead sponsor
Immunomic Therapeutics, Inc.
Industry
Eligibility
18 Years to 63 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 25, 2026, 2:05 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

COVID-2019 Testing and Vaccination Among African American and Latinx Public Housing Residents

NCT04542395
View directory record Official record
Conditions
Coronavirus
Interventions
Increasing Willingness and Uptake of COVID-19 Testing and Vaccination
Behavioral
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2022 · Synced Oct 25, 2026, 2:05 PM EDT
Not yet recruiting Not applicable Interventional

ORASIS in Breast Reconstruction

NCT07670754
View directory record Official record
Conditions
DIEP Flap, Breast Reconstruction, Breast Cancer
Interventions
Use of ORASIS Device
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 25, 2026, 2:05 PM EDT
Active, not recruiting Phase 4 Interventional

Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE

NCT03581877
View directory record Official record
Conditions
Pulmonary Embolism, Pulmonary Hypertension, Thromboembolism, Right Ventricular Dysfunction
Interventions
Alteplase, EKOS
Drug · Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 89 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Bay Shore, New York • Queens, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 25, 2026, 2:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART

NCT00270205
View directory record Official record
Conditions
HIV Infections
Interventions
LC002 standard vaccination, LC002 high-dose vaccination, LC002 placebo vaccination
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
5
States / cities
Sacramento, California • Chicago, Illinois • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 25, 2026, 2:05 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT

NCT02010203
View directory record Official record
Conditions
Bladder Cancer
Interventions
HS-410, Placebo, BCG
Biological
Lead sponsor
Heat Biologics
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
19
States / cities
Los Angeles, California • Sherman Oaks, California • Torrance, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 25, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Results available

An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

NCT03518086
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mirikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
98
States / cities
Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 25, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

Green Tea or Polyphenon E in Preventing Lung Cancer in Former Smokers With Chronic Obstructive Pulmonary Disease

NCT00363805
View directory record Official record
Conditions
Lung Cancer Prevention
Interventions
green tea, Polyphenon E, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Sherry Chow
Other
Eligibility
40 Years to 80 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
3
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 28, 2013 · Synced Oct 25, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 25, 2026, 2:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Influenza Vaccine in Lung Transplant Patients - T Cells

NCT04533061
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 25, 2026, 2:05 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)

NCT01632241
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo plus standard therapy, Belimumab 10 mg/kg plus standard therapy, Standard therapy
Biological · Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
64
States / cities
Birmingham, Alabama • Covina, California • La Palma, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 25, 2026, 2:05 PM EDT
Completed Not applicable Interventional

Green Tea in Breast Cancer Patients

NCT00949923
View directory record Official record
Conditions
Incident Breast Cancer
Interventions
tea capsule
Dietary Supplement
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2018 · Synced Oct 25, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children

NCT03292588
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 17 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
9
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 25, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier

NCT02581410
View directory record Official record
Conditions
Herpes Zoster
Interventions
GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years and older
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
32
States / cities
Huntsville, Alabama • Daly City, California • Los Gatos, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 25, 2026, 2:05 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

PEG3350 vs Senna After Urogyn Surgery

NCT06825260
View directory record Official record
Conditions
Obstructive Defecation Syndrome, Postoperative Constipation
Interventions
Senna, Polyethylene glycol 3350
Drug
Lead sponsor
St. Joseph's Health, New York
Other
Eligibility
18 Years and older · Female only
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 25, 2026, 2:05 PM EDT
Completed Phase 3 Interventional

Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

NCT06100939
View directory record Official record
Conditions
Keratoconus
Interventions
Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment, Placebo and sham treatment
Combination Product
Lead sponsor
Epion Therapeutics
Industry
Eligibility
8 Years to 45 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
13
States / cities
Rowland Heights, California • San Francisco, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 25, 2026, 2:05 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity

NCT02873819
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Oral Cavity
Interventions
GL-0817, Hiltonol, Sargramostim, cyclophosphamide, Placebo
Drug
Lead sponsor
Gliknik Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 25, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

Darbepoetin Administration to Preterm Infants

NCT00334737
View directory record Official record
Conditions
Infant, Newborn
Interventions
Darbepoetin Alfa Injection, erythropoietin alfa injection, sham injection
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
1 Hour to 49 Hours
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
3
States / cities
Denver, Colorado • Ogden, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 25, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine

NCT03560245
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Bryostatin, Placebo
Drug · Other
Lead sponsor
Neurotrope Bioscience, Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
28
States / cities
Fresno, California • Los Alamitos, California • Santa Ana, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 25, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Results available

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

NCT01989572
View directory record Official record
Conditions
Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Mucosal Melanoma, Ocular Melanoma With Extraocular Extension, Recurrent Melanoma, Recurrent Uveal Melanoma, Small Size Posterior Uveal Melanoma, Stage IIA Cutaneous Melanoma AJCC v6 and v7, Stage IIA Uveal Melanoma AJCC v7, Stage IIB Cutaneous Melanoma AJCC v6 and v7, Stage IIB Uveal Melanoma AJCC v7, Stage IIC Cutaneous Melanoma AJCC v6 and v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIA Uveal Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Placebo, Sargramostim, Tyrosinase Peptide
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
815 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
148
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 117 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 25, 2026, 2:05 PM EDT
Completed Early Phase 1 Interventional

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

NCT06366451
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Rilvegostomig, Volrustomig, Sabestomig, AZD9592, Pembrolizumab, AZD9592 + Rilvegostomig, AZD9592 + Volrustomig, AZD9592 + Sabestomig, AZD9592 + Pembrolizumab
Biological · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Sacramento, California • The Bronx, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 25, 2026, 2:05 PM EDT